US diabetes care technology company Embecta Corp. (NASDAQ: EMBC) announced on Friday that it has completed its acquisition of UK-based medical device manufacturer Owen Mumford Holdings Limited.

The deal includes an upfront cash payment of GBP100m and up to GBP50m in performance-based payments tied to net sales of the Aidaptus auto-injector platform over the three years following closing.

Embecta said the transaction advances its shift towards a broader medical supplies business serving pharmaceutical partners and chronic care patients across obesity, diabetes, autoimmune diseases and anaphylaxis. The acquisition adds a drug-delivery platform supported by intellectual property, including the next-generation Aidaptus auto-injector, and expands Embecta's chronic care device portfolio.

The combined business will integrate Owen Mumford's device design, moulding and assembly capabilities with Embecta's global commercial network and large-scale manufacturing operations, aiming to increase geographic reach and operational efficiency.